Adicet Bio has initiated a Phase 1 clinical trial for ADI-270, a novel cancer therapy. This trial focuses on patients with advanced clear cell renal cell carcinoma (ccRCC), a prevalent and aggressive kidney cancer subtype. Solid tumors, like ccRCC, have yet to experience the same therapeutic advancements as blood cancers treated with CAR T cell therapies. ADI-270 offers the potential to change this. Preclinical data suggests ADI-270 effectively infiltrates tumors, resists the immunosuppressive tumor environment, and exhibits potent anti-tumor activity. Preliminary clinical data from this trial is anticipated in the first half of 2025.
This Phase 1 trial is a multicenter, open-label study designed to assess ADI-270 as a monotherapy in adults with relapsed or refractory ccRCC. Participants will receive a single dose of ADI-270 after lymphodepletion, with the potential for a second dose if specific criteria are met. The trial will evaluate the therapy’s safety, tolerability, pharmacokinetics, and anti-tumor activity, including overall response rate, response duration, and disease control rate.
ADI-270 is an “off-the-shelf” allogeneic gamma delta CAR T cell therapy. It targets CD70, a protein highly expressed in various solid and hematological malignancies. This therapy uses the natural receptor CD27 as the binding moiety and incorporates a dominant negative form of the transforming growth factor-β receptor II (dnTGFβRII). This design aims to enhance ADI-270’s resilience against the immunosuppressive tumor microenvironment and improve its persistence by reducing susceptibility to host rejection. With the inherent tumor-infiltrating properties of gamma delta 1 T cells, ADI-270 aims to enhance clinical outcomes for RCC and other CD70+ tumor patients.
Renal cell carcinoma (RCC) comprises the majority of kidney tumors, with clear cell RCC (ccRCC) being the most common and aggressive subtype. CcRCC often spreads to the lungs, liver, and bones in the kidney’s proximal nephron and tubular epithelium. A significant portion of RCC diagnoses are initially locally advanced or metastatic, and a considerable number of patients develop metastatic disease post-nephrectomy. While localized RCC has a high 5-year survival rate, the prognosis significantly worsens for advanced disease. This underscores the urgent need for effective therapies like ADI-270. Adicet Bio, the company developing ADI-270, focuses on allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. They are developing a pipeline of “off-the-shelf” gamma delta T cells engineered with CARs to promote durable responses in patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.